和铂医药-B获NMPA批准HBM7575(SKB575)针对特应性皮炎的新药临床试验申请

美股速递
Mar 09

中国国家药品监督管理局(NMPA)已正式批准和铂医药-B(HBM HOLDINGS-B)提交的HBM7575(亦称SKB575)新药临床试验申请。该药物将用于治疗特应性皮炎,标志着公司在免疫性疾病治疗领域的研发取得重要进展。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10